Literature DB >> 11999653

Circulating hepatocyte growth factor as a diagnostic marker of thrombus formation in patients with cerebral infarction.

Akira Matsumori1, Hajime Takano, Jun-ei Obata, Satoshi Takeda, Naohiko Tsuyuguchi, Koh Ono, Masaharu Okada, Tadashi Miyamoto, Tomokazu Ohnishi, Yasushi Daikuhara, Shigetake Sasayama.   

Abstract

Circulating levels of hepatocyte growth factor (HGF) are increased in the early stage of an acute myocardial infarction because of arterial thrombosis. The purpose of this study was to use a new sensitive enzyme-linked immunosorbent assay to investigate whether circulating HGF is increased in patients with cerebral infarction. Circulating HGF was measured in 32 patients with cerebral infarction on admission to hospital and on days 2, 3, 7 and 14 after the onset of symptoms. Serum HGF levels exceeded the mean value +2SD (329pg/ml) measured in controls in 10 of 20 patients (50%) within 6 h after onset and in 15 of 32 patients (47%) within 24 h. Plasma D-dimer was increased in more than half of the patients with elevated HGF values. HGF levels in 16 patients who were measured serially were persistently increased throughout the study period. The results suggests that circulating HGF is a reliable early marker of cerebral infarction, and that this new sensitive HGF assay may be useful for diagnosing cerebral thrombosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11999653     DOI: 10.1253/circj.66.216

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  7 in total

Review 1.  Emerging risk factors in women.

Authors:  Kathryn M Rexrode
Journal:  Stroke       Date:  2010-10       Impact factor: 7.914

2.  Hepatocyte growth factor and the risk of ischemic stroke developing among postmenopausal women: results from the Women's Health Initiative.

Authors:  Swapnil N Rajpathak; Tao Wang; Sylvia Wassertheil-Smoller; Howard D Strickler; Robert C Kaplan; Aileen P McGinn; Rachel P Wildman; Daniel Rosenbaum; Thomas E Rohan; Philipp E Scherer; Mary Cushman; Gloria Y F Ho
Journal:  Stroke       Date:  2010-03-04       Impact factor: 7.914

3.  Hepatocyte Growth Factor Is Positively Associated With Risk of Stroke: The MESA (Multi-Ethnic Study of Atherosclerosis).

Authors:  Elizabeth J Bell; Nicholas B Larson; Paul A Decker; James S Pankow; Michael Y Tsai; Naomi Q Hanson; Christina L Wassel; W T Longstreth; Suzette J Bielinski
Journal:  Stroke       Date:  2016-10-11       Impact factor: 7.914

Review 4.  Diagnosis of hepatocellular carcinoma.

Authors:  Asmaa I Gomaa; Shahid A Khan; Edward L S Leen; Imam Waked; Simon D Taylor-Robinson
Journal:  World J Gastroenterol       Date:  2009-03-21       Impact factor: 5.742

Review 5.  Hepatocyte growth factor, a biomarker of macroangiopathy in diabetes mellitus.

Authors:  Hiroyuki Konya; Masayuki Miuchi; Kahori Satani; Satoshi Matsutani; Taku Tsunoda; Yuzo Yano; Tomoyuki Katsuno; Tomoya Hamaguchi; Jun-Ichiro Miyagawa; Mitsuyoshi Namba
Journal:  World J Diabetes       Date:  2014-10-15

6.  Clinical significance of serum hepatocyte growth factor (HGF) levels in hepatocellular carcinoma.

Authors:  S Karabulut; F Tas; F Akyüz; A C Ormeci; M Serilmez; H O Soydinç; S Vatansever; V Yasasever
Journal:  Tumour Biol       Date:  2013-10-20

7.  Improved bladder contractility after transplantation of human mesenchymal stem cells overexpressing hepatocyte growth factor into underactive bladder from bladder outlet obstruction models of rats.

Authors:  Jae Heon Kim; Hee Jo Yang; Sung Sik Choi; Seung U Kim; Hong J Lee; Yun Seob Song
Journal:  PLoS One       Date:  2021-12-22       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.